Comparative Pharmacology
Head-to-head clinical analysis: LUMENHANCE versus OPTIMARK IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMENHANCE versus OPTIMARK IN PLASTIC CONTAINER.
LUMENHANCE vs OPTIMARK IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMENHANCE is a contrast agent that increases signal intensity in magnetic resonance imaging by shortening T1 relaxation time, enhancing tissue visualization.
Gadolinium-based paramagnetic contrast agent. The gadolinium ion (Gd3+) has seven unpaired electrons and a high magnetic moment, which enhances the relaxation rates of surrounding water protons in tissues, increasing signal intensity on T1-weighted magnetic resonance imaging (MRI) scans.
1 mg intravenously once daily
0.2 mL/kg (0.1 mmol/kg) IV bolus; may repeat once within 30 minutes for total dose of 0.4 mL/kg (0.2 mmol/kg) if needed for contrast-enhanced MRI.
None Documented
None Documented
Terminal elimination half-life is 8–10 hours in healthy adults; half-life may increase up to 15 hours in moderate hepatic impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with severe renal impairment (GFR < 30 mL/min), half-life may be prolonged up to 30 hours.
LUMENHANCE is primarily eliminated via renal excretion (70% unchanged) and biliary/fecal excretion (25% as metabolites). Approximately 5% is eliminated via other routes.
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% eliminated in feces.
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent